Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin

Journal of Clinical Virology

Volumn 52, Issue 4, 2011, Pages 363-366

  Lyoo, KwangSoo ^a   Hur, Wonhee ^a   Choi, Jung Eun ^a   Hong, Sung Woo ^a   Kim, Chang Wook ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Choi, Sang Wook ^a   Shin, Eui Cheol ^b   Yoon, Seung Kew ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Hepatitis C virus; IL28B; Korean; Single nucleotide polymorphisms; Sustained virological response

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 82755197774     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.08.006     Document Type: Article

References (17)

1. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
2. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
3. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
4. Afdhal N.H., McHutchison J.G., Zeuzem S., Mangia A., Pawlotsky J.M., Murray J.S., et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011, 53:336-345.
5. Ito K., Higami K., Masaki N., Sugiyama M., Mukaide M., Saito H., et al. The rs8099917 polymorphism, determined by a suitable genotyping method, is a better predictor for response to pegylated interferon-{alpha}/ribavirin therapy in Japanese patients than other SNPs associated with IL28B. J Clin Microbiol 2011, 49:1853-1860.
6. Lange C.M., Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011, [Epub ahead of print].
7. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
8. Missiha S., Heathcote J., Arenovich T., Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007, 102:2181-2188.
9. Kwon J.H., Bae S.H., Choi J.Y., Yoon S.K., Byun K.S., Paik S.W., et al. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. Korean J Intern Med 2009, 24:203-211.
10. Jeong S.W., Kim J.D., Woo H.Y., You C.R., Lee S.W., Song M.J., et al. Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response. Korean J Hepatol 2009, 15:338-349.
11. Ioannou G.N., Dominitz J.A., Weiss N.S., Heagerty P.J., Kowdley K.V. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 2003, 37:795-801.
12. Kimball P., Elswick R.K., Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001, 65:510-516.
13. Moghaddam A., Melum E., Reinton N., Ring-Larsen H., Verbaan H., Bjoro K., et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011, 53:746-754.
14. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129.
15. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345.
16. Stattermayer A.F., Stauber R., Hofer H., Rutter K., Beinhardt S., Scherzer T.M., et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011, 9:344-350.
17. Chen J.Y., Lin C.Y., Wang C.M., Lin Y.T., Kuo S.N., Shiu C.F., et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun 2011, 12:300-309.